The IMMP2L Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population designed to eliminate IMMP2L gene function. This product is a heterogeneous collection of A-549 cells bearing disruptions in the IMMP2L locus, generated by CRISPR/Cas9-mediated genome editing without subsequent clonal isolation. As a polyclonal pool, it retains the genetic heterogeneity of the edited population, making it suitable for experiments requiring a broad sampling of knockout effects while minimizing clonal artifacts.
The A-549 host cell line originates from a human lung adenocarcinoma in a 58-year-old Caucasian male and is characterized by a KRAS G12S activating mutation and wild-type p53. These type II alveolar epithelial-like cells are a mainstay in cancer research due to their robust growth, well-annotated genomic landscape, and utility in drug metabolism studies. Their KRAS-driven malignant phenotype makes them especially valuable for probing interactions between oncogenic signaling and mitochondrial homeostasis.
IMMP2L encodes the catalytic subunit of the mitochondrial inner membrane peptidase (IMP) complex, which processes presequence-containing proteins after their import through the TOM/TIM translocases. This enzyme works closely with its non-catalytic partner IMMP1L and the mitochondrial processing peptidase (MPP) to ensure correct maturation of precursor proteins, including components of oxidative phosphorylation complexes. IMMP2L expression is regulated by the transcription factors NRF1, PPARGC1A, and TFAM, linking it to mitochondrial biogenesis programs. Downstream, its activity is crucial for the stability of OPA1, which controls cristae remodeling, and for the processing of PINK1, a key mitophagy initiator. Additionally, IMMP2L is functionally connected to the m-AAA proteases OMA1 and YME1L, situating it at a nexus of mitochondrial protein quality control and turnover pathways.
In A-549 cells, knockout of IMMP2L disrupts IMP function, leading to impaired cleavage of mitochondrial precursors and defective assembly of respiratory chain complexes. This results in mitochondrial dysfunction manifested by reduced membrane potential and altered mitophagic flux. Given the KRAS-driven metabolic reprogramming in A-549 cells, loss of IMMP2L may further stress mitochondrial proteostasis and provoke compensatory metabolic shifts, offering a model to study how mitochondrial processing defects intersect with cancer cell bioenergetics. The system is particularly useful for examining whether IMMP2L deficiency sensitizes lung adenocarcinoma cells to chemotherapeutic agents or targeted inhibitors that exploit mitochondrial vulnerabilities.
Researchers can employ these polyclonal knockout cells in a range of assays to dissect mitochondrial biology. Metabolic studies using Seahorse analyzers enable real-time assessment of oxidative phosphorylation and glycolysis, while JC-1 staining provides readouts of mitochondrial membrane potential. Mitophagy flux can be measured by co-localization of LC3B with TOMM20, and immunoblotting or RT-qPCR can quantify changes in OXPHOS subunits and mitochondrial gene expression. Additional experimental avenues include drug resistance profiling, apoptosis analysis via Annexin V, and investigation of the mitochondrial unfolded protein response. For further technical information, please contact Ascent Research.
